Letibotulinumtoxina - Hugel

Drug Profile

Letibotulinumtoxina - Hugel

Alternative Names: BoNT/A-DP; Botulax; Botulinum toxin type A - Hugel

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hugel
  • Developer Croma Pharma; Hugel
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Glabellar lines
  • Phase III Cerebral palsy; Facial-wrinkles

Most Recent Events

  • 11 Sep 2017 Phase-III clinical trials in Facial wrinkles in South Korea (IM) (NCT03408236)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Feb 2016 Phase-III clinical trials in Glabellar lines in USA, Germany, Poland (IM) (NCT02677298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top